Possible Link Between Spousal Depressed Mood, Cancer Survivor Quality of Life
the Cancer Therapy Advisor take:
Spousal depressed mood and poor health-related quality of life (HRQoL) may increase the risk of depressed mood and poor HRQoL in cancer survivors, especially female survivors, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
A longitudinal study investigated data from the 2004-2012 Medical Expenditures Panel Survey and another sample of cancer-free dyads.
The data involved reports of depressed mood, psychologic distress, and mental and physical health-related quality of life (HRQoL) from cancer survivors and their spouses (n = 910 dyads). The cancer survivors and their spouses reported these factors at two time points (T1/T2).
The impact of psychosocial factors at T1 on depressed mood at T2 was evaluated by dyadic multilevel models—sociodemographics, cancer type, survivor treatment status, and depressed mood at T1 were all controlled.
Results showed that cancer survivors with spouses who reported depressed mood at T1 were 4.27 times more likely to demonstrate depressed mood at the T2 report (95% CI: 2.01, 9.07].
When spouses reported a better mental and physical HRQoL at T1, there was a 30% decrease in cancer survivor depressed mood at T2.
The study suggests that evaluations should be conducted to see if the incorporation of spousal care into psychooncology and survivorship programs will help improve survivor outcomes.
Spousal depressed mood and poor health-related quality of life may increase risk of depressed mood in cancer survivors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer